• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    CG Oncology, Inc. - Common stock (NQ:CGON)

    74.23 -0.44 (-0.59%)
    Streaming Delayed Price Updated: 12:13 PM EDT, Sep 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about CG Oncology, Inc. - Common stock

    < Previous 1 2 3 4 5 Next >
    News headline image
    CG Oncology to Present at Upcoming Investor Conferences in September
    From CG Oncology Inc.
    Via GlobeNewswire
    CG Oncology (NASDAQ:CGON) Flaunts a Perfect Technical Breakout Setup ↗
    Via Chartmill
    News headline image
    CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
    From CG Oncology Inc.
    Via GlobeNewswire
    News headline image
    CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
    Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder... 
    From CG Oncology Inc.
    Via GlobeNewswire
    News headline image
    CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead ↗
    CG Oncology (NASDAQ:CGON) Chief Executive Officer Arthur outlined the company’s upcoming clinical and regulatory milestones for cretostimogene during a presentation at the Goldman Sachs Global... 
    Via MarketBeat
    Topics Initial Public Offering
    CG Oncology Inc (NASDAQ:CGON) Shows Perfect Technical Rating and Strong Setup Quality for Potential Breakout ↗
    Via Chartmill
    News headline image
    CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push ↗
    CG Oncology (NASDAQ:CGON) is focused on advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer, Chief Executive Officer Arthur Kuan said during a discussion at the... 
    Via MarketBeat
    Topics Initial Public Offering
    News headline image
    CG Oncology to Present at Upcoming Investor Conferences in June
    From CG Oncology Inc.
    Via GlobeNewswire
    News headline image
    CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference ↗
    CG Oncology (NASDAQ:CGON) executives used an RBC Capital Markets fireside chat to outline recent clinical data for cretostimogene, the company’s investigational therapy for non-muscle invasive bladder... 
    Via MarketBeat
    Topics Initial Public Offering
    News headline image
    SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
    From CG Oncology Inc.
    Via GlobeNewswire
    News headline image
    CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
    From CG Oncology Inc.
    Via GlobeNewswire
    News headline image
    CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears ↗
    CG Oncology (NASDAQ:CGON) executives said the company remains on track to complete a rolling biologics license application for cretostimogene in BCG-unresponsive high-risk non-muscle invasive bladder... 
    Via MarketBeat
    Topics Initial Public Offering
    News headline image
    CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
    From CG Oncology Inc.
    Via GlobeNewswire
    News headline image
    CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings ↗
    CG Oncology (NASDAQ:CGON) reported mixed results for Q1, with losses of 71 cents per share and sales of $1.083 million. Analysts have adjusted price targets. 
    Via Benzinga
    News headline image
    CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
    From CG Oncology Inc.
    Via GlobeNewswire
    News headline image
    CG Oncology to Present at Upcoming Investor Conferences in May
    From CG Oncology Inc.
    Via GlobeNewswire
    News headline image
    As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? ↗
    This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates. 
    Via The Motley Fool
    News headline image
    This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗
    This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth
    In a classic case of "selling the news," shares of ImmunityBio, Inc. (NASDAQ: IBRX) took a sharp dive on Wednesday, March 4, 2026, plummeting over 13% to close at $9.02. The sell-off came as a surprise... 
    Via MarketMinute
    Topics Earnings Economy
    News headline image
    CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
    From CG Oncology Inc.
    Via GlobeNewswire
    News headline image
    CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference
    From CG Oncology Inc.
    Via GlobeNewswire
    News headline image
    CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale ↗
    This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients with limited treatment options. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
    As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that... 
    Via MarketMinute
    Topics Intellectual Property
    What's going on in today's session ↗
    Via Chartmill
    Keep an eye on the top gainers and losers in Friday's session. ↗
    Via Chartmill
    News headline image
    CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC
    From CG Oncology Inc.
    Via GlobeNewswire
    News headline image
    CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From CG Oncology Inc.
    Via GlobeNewswire
    News headline image
    This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗
    A full exit during a volatile stretch raises a sharper question than timing alone. 
    Via The Motley Fool
    News headline image
    SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
    From CG Oncology Inc.
    Via GlobeNewswire
    News headline image
    New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
    From CG Oncology Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.